EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSNBRG00000021311
Gene Symbol: LOC102795048
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSNBRG00000006248
Gene Symbol: KCNQ2
1 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSNBRG00000016605
Gene Symbol: KCNQ3
1 Cross references
191 Possible Orthologues:

Presenilin-1-Like

Ensembl ID : ENSNBRG00000004519
Gene Symbol: LOC102790300
3 Cross references
200 Possible Orthologues:

Presenilin-2-Like

Ensembl ID : ENSNBRG00000020606
Gene Symbol: LOC102786520
3 Cross references
205 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme-Like

Ensembl ID : ENSNBRG00000010840
Gene Symbol: LOC102793907
2 Cross references
404 Possible Orthologues:

Probable Histone Deacetylase 1-B-Like

Ensembl ID : ENSNBRG00000022221
Gene Symbol: LOC102789841
3 Cross references
250 Possible Orthologues:

Probable Histone Deacetylase 1-B-Like

Ensembl ID : ENSNBRG00000009739
Gene Symbol: LOC102777098
4 Cross references
255 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSNBRG00000023130
Gene Symbol: PTGDR2
2 Cross references
135 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSNBRG00000020097
Gene Symbol: PTGER3
3 Cross references
194 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSNBRG00000019613
Gene Symbol: LOC102793656
3 Cross references
167 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSNBRG00000010138
Gene Symbol: LOC102796312
3 Cross references
164 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).